The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy

European Journal of Pharmacology

Volumn 404, Issue 1-2, 2000, Pages 1-12

  Moret, Chantal ^a   Briley, Mike ^b  

^a NeuroBiz Consulting and Communication   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT (5 hydroxytryptamine, serotonin) release; 5 HT (5 hydroxytryptamine, serotonin) synthesis; 5 HT(1B D) receptor; Anxiety; Depression; Desensitisation; Obsessive compulsive disorder; Psychiatric disorder; Supersensitive; Target

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 4 AMINOBUTYRIC ACID; 5 CARBAMOYLTRYPTAMINE; 5 HYDROXYTRYPTOPHAN; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CITALOPRAM; CYANOPINDOLOL; DIAZEPAM; DOPAMINE; FLUMAZENIL; GLUTAMIC ACID; GROWTH HORMONE; IMIPRAMINE; METITEPINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; PAROXETINE; PROPRANOLOL; RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPIPERONE; SUMATRIPTAN; UNINDEXED DRUG; ZOLMITRIPTAN;

ANXIETY; DEPRESSION; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; MENTAL DISEASE; NONHUMAN; OBSESSION; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE;

ANIMALS; ANXIETY; DEPRESSION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 0034666574     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00581-1     Document Type: Review

References (118)

1. Auerbach S.B., Rutter J.J., Juliano P.J. Substituted piperazine and indole compounds increase extracellular serotonin in rat diecephalon as determined by in vivo microdialysis. Neuropharmacology. 30:1991;307-311.
2. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
3. Barth T., Rex A., Domeney A.M., Fink H. Effects of cholecystokinin fragments in three animal models of anxiety. Elsner N., Heisenberg M. Gene - Brain - Behaviour. 1993;621-645 Georg Thieme Verlag, Stuttgart.
4. 1B characterizing agents in the mouse elevated plus-maze. Life Sci. 47:1990;195-203.
5. 1B receptors in the rat brain. Eur. J. Pharmacol. 294:1995;531-540.
6. 1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology. 117:1995;358-363.
7. Boutrel B., Franc B., Hen R., Hamon M., Adrien J. Key role of 5-HT1B receptors in the regulation of paradoxical sleep as evidenced in 5-HT1B knock-out mice. J. Neurosci. 19:1999;3204-3212.
8. Bradley P.B., Engel G., Feniuk W., Fozard J.R., Humphrey P.P.A., Middlemiss D.N., Mylecharane E.J., Richardson B.P., Saxena P.R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 25:1986;563-576.
9. Briley M., Chopin P. Serotonin in anxiety. Evidence from animal models. Sandler M., Coppen A., Harnett S. 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas. 1991;177-197 Oxford Univ. Press, Oxford.
10. Briley M., Chopin P. Is anxiety associated with a hyper- or hypo-serotonergic state? Palomo T., Archer T. Strategies for Studying Brain Disorders, Depression, Anxiety and Drug Abuse Disorders. vol. 1:1994;197-209 Editorial Complutence, Donoso Cortés, Madrid.
11. 1B/D receptors. Baumgarten H.G., Göthert M. Serotoninergic Neurons and 5-HT Receptors in the CNS. 1997;269-291 Springer-Verlag, Berlin.
12. Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 16:1993;387-400.
13. Broekkamp C.L., Berendsen H.H., Jenck F., Van Delft A.M. Animal models for anxiety and response to serotonergic drugs. Psychopathology. 22(Suppl. 1):1989;2-12.
14. Bruinvels A.T., Palacios J.M., Hoyer D. Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;569-582.
15. 1B knockout mice. Behav. Neurosci. 113:1999;587-601.
16. 1Dβ-like autoreceptors in the guinea-pig brain cortex. Naunyn-Schmiedeberg′s Arch. Pharmacol. 353:1996;281-289.
17. 3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin. Brain Res. 704:1995;153-166.
18. 1B receptor gene deletion. Baumgarten H.G., Göthert M. Serotoninergic Neurons and 5-HT Receptors in the CNS. 1997;351-365 Springer-Verlag, Berlin.
19. Chaouloff F., Aguerre S., Mormede P. GR 127935 and (+)-WAY 100135 do not affect TFMPP-induced inhibition of 5-HT synthesis in the midbrain and hippocampus of Wistar-Kyoto rats. Neuropharmacology. 37:1998;1159-1167.
20. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., Heninger G.R. Serotonin function in obsessive-compulsive disorder. Arch. Gen. Psychiatry. 45:1988;177-185.
21. Chopin P., Briley M. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol. Sci. 8:1987;383-388.
22. 1B/D receptor ligands. Pharmacol. Ther. 62:1994;385-405.
23. 1B and benzodiazepine receptor ligands in the light/dark box anxiety model in mice. Soc. Neurosci. 24:1998;601.
24. 1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan. Psychol. Med. 28:1998;295-300.
25. Clement H.W., Schäfer F., Ruwe C., Gemsa D., Wesemann W. Stress-induced changes of extracellular 5-hydroxyindoleacetic acid concentrations followed in the nucleus raphe dorsalis and the frontal cortex of the rat. Brain Res. 614:1993;117-124.
26. Clément Y., Hossein Kia K., Daval G., Vergé D. An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Brain Res. 709:1996;229-242.
27. Cowen P.J. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin. Neuropharmacol. 16:1993;S6-S18. (Suppl.).
28. 1D autoreceptors. Br. J. Pharmacol. 114:1995;1107-1109.
29. Deacon R., Gardner C.R. Benzodiazepine and 5-HT ligands in a rat conflict test. Br. J. Pharmacol. 88:1986;. 330 pp.
30. Di Chiara G. In vivo brain dialysis of neurotransmitters. Trends Pharmacol. Sci. 11:1990;116-121.
31. Dolberg O.T., Iancu I., Sasson Y., Zohar J. The pathogenesis and treatment of obsessive compulsive disorder. Clin. Neuropharmacol. 19:1996;129-147.
32. Dolberg O.T., Sasson Y., Cohen R., Zohar J. The relevance of behavioral probes in obsessive-compulsive disorder. Eur. J. Neuropsychopharmacol. 5:1995;161-162.
33. 1B receptors in an animal model of depression. Neuropharmacology. 30:1991;101-105.
34. Feighner J.P., Boyer W.F. Selective serotonin reuptake inhibitors, Wiley, Chichester. 1991.
35. Feldberg W., Myers R.D. Effects on temperature of 5-hydroxytryptamine, adrenaline and noradrenaline injected into the cerebral ventricles or the hypothalamus of cats. J. Physiol. 173:1964;25-30.
36. Fernstrom J.D., Wurtmann R.J. Brain serotonin content: increase following ingestion of carbohydrate diet. Science. 174:1971;1023-1025.
37. 3H]GABA in human, but not in rabbit, neocortex. Neurosci. Lett. 209:1996;210-214.
38. 1Dβ receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;451-454.
39. Fish E.W., Sekinda M., Ferrari P.F., Dirks A., Miczek K.A. Distress vocalizations in maternally separated mouse pups: modulation via 5-HT(1A), 5-HT(1B) and GABA(A) receptors. Psychopharmacology. 149:2000;277-285.
40. Franceschini R., Cataldi A., Garibaldi A., Cianciosi P., Scardamoglia A., Barracca T., Rolandi E. The effects of sumatriptan on pituitary secretion in man. Neuropharmacology. 33:1994;235-239.
41. 1B receptor inverse agonist 1′-methyl-5-[[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4(- piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J. Med. Chem. 41:1998;1218-1235.
42. Golden R.N., Gilmore J. Serotonin and mood disorder. Psychiatr. Ann. 20:1990;580-586.
43. Gorzalka B.B., Mendelson S.D., Watson NV. Serotonin receptor subtypes and sexual behaviour. Ann. N. Y. Acad. Sci. 600:1990;435-446.
44. Göthert M., Schlicker E. Regulation of 5-HT release in the CNS by presynaptic 5-HT autoreceptors and by 5-HT heteroreceptors. Baumgarten H.G., Göthert M. Serotoninergic Neurons and 5-HT Receptors in the CNS. 1997;307-350 Springer-Verlag, Berlin.
45. 1D receptor subtypes. Trends Pharmacol. Sci. 17:1996;103-105.
46. 1B receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo - Comparison with RU 24969. Eur. J. Pharmacol. 209:1991;249-252.
47. Hjorth S., Suchowski C.S., Galloway M.P. Evidence for 5-HT autoreceptor-mediated, nerve impulse-independent, control of 5-HT synthesis in the rat brain. Synapse. 19:1995;170-176.
48. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
49. Huang Y.Y., Grailhe R., Arango V., Hen R., Mann J.J. Relationship of psychopathology to the human serotonin 1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology. 21:1999;238-246.
50. Jacobs B.L. Serotonin and bahaviour: emphasis on motor control. J. Clin. Psychiatry. 52:1991;17-23. Suppl.
51. Jouvet M. Neurophysiology of the states of sleep. Physiol. Rev. 47:1967;117-177.
52. Kawahara H., Yoshida M., Yokoo H., Nishi M., Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci. Lett. 162:1993;81-84.
53. 1B receptors. Soc. Neurosci. Abstr. 16:1990;1035.
54. Lauder J.M. Hormonal and humoral influences on brain development. Psychoneuroendocrinology. 8:1983;121-155.
55. Lawrence A.J., Marsden C.A. Terminal autoreceptor control of 5-hydroxytryptamine release as measured by in vivo microdialysis in the conscious guinea pig. J. Neurochem. 58:1992;142-146.
56. McNamara M.G., Kelly J.P., Leonard B.E. Some behavioural effects of methiothepin in the olfactory bulbectomised rat model of depression. Med. Sci. Res. 23:1995;583-585.
57. 1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-Yl)indole. J. Med. Chem. 33:1990;2087-2093.
58. 1A agonist, in the learned helplessness paradigm: evidence for a postsynaptic mechanism. Behav. Brain Res. 38:1990;135-144.
59. 3 receptors in the control of 5-HT release in rat hippocampus in vivo. Br. J. Pharmacol. 106:1992;139-142.
60. 1B antagonist blocks effects of RU 24969 on locomotor, but not investigatory, activity in rats. Soc. Neurosci. 23:1997;519.
61. 1B/1D antagonistic activity: a new approach toward efficient antidepressants. J. Med. Chem. 43:2000;1149-1157.
62. 1B receptors mediating inhibition of acetylcholine release. Eur. J. Pharmacol. 129:1986;333-337.
63. 1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur. J. Pharmacol. 375:1999;359-365.
64. Moret C., Briley M. Which 5-HT receptors are involved in the modulation of 5-HT synthesis by the 5-HT uptake blocker, citalopram? Br. J. Pharmacol. 108:1993;. 96 pp.
65. Moret C., Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur. J. Pharmacol. 295:1996;189-197.
66. 1D autoreceptors and 5-HT synthesis in guinea pig brain. Soc. Neurosci. 22:1996;1332.
67. Moret C., Briley M. 5-HT Autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus. Neuropharmacology. 36:1997;1713-1723.
68. Moret C., Briley M. Ex vivo inhibitory effect of the 5-HT uptake blocker citalopram on 5-HT synthesis. J. Neural Transm. 104:1997;147-160.
69. 1D on basal and stimulated growth hormone secretion. J. Clin. Endocrinol. Metab. 80:1995;1973-1977.
70. Neumaier J.F., Petty F., Kramer G.L., Szot P., Hamblin M.W. Learned helplessness increases 5-hydroxytryptamine1B receptor mRNA levels in the rat dorsal raphe nucleus. Biol. Psychiatry. 41:1997;668-674.
71. Olivier B., Molewijk H.E., van der Heyden J.A., van Oorschot R., Ronken E., Mos J., Miczek K.A. Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci. Biobehav. Rev. 23:1998;215-227.
72. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 40:1994;288-295.
73. Pei Q., Zetterstrom T., Fillenz M. Tail pinch-induced changes in the turnover and release of dopamine and 5-hydroxytryptamine in different brain regions of the rat. Neuroscience. 35:1990;133-138.
74. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
75. Pellow S., Johnston A.L., File S.E. Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat. J. Pharm. Pharmacol. 39:1987;917-928.
76. Petty F., Kramer G., Wilson L. Prevention of learned helplessness: in vivo correlation with cortical serotonin. Pharmacol. Biochem. Behav. 43:1992;361-367.
77. Pian K.L., Westenberg H.G., van Megen H.J., den Boer J.A. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology. 140:1998;365-370.
78. Pigott T.A., L'Heureux F., Bernstein S.E., Hill J.L., Murphy D.L. A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazine (mCPP) in patients with obsessive-compulsive disorder. NCDEU Annual Meeting. May 26-29; Orlando:1992.
79. Pigott, T.A., Murphy, D.L., Brooks, A., 1993. Pharmacological probes in OCD: support for selective 5-HT dysregulation. Presented at the First International Obsessive Compulsive Disorder Congress, Capri, Italy, 12-13 March.
80. 1B receptor knockout - behavioral consequences. Behav. Brain Res. 73:1996;305-312.
81. 1D receptors in cortical extracellular 5-HT release in guinea-pigs on exposure to the elevated plus maze. J. Psychopharmacol. 10:1996;219-224.
82. Rex A., Marsden C.A., Fink H. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology. 110:1993;490-496.
83. 1D receptor antagonist, GR 127935, on in vivo 5-HT release, synthesis and turnover in the guinea pig frontal cortex. Br. J. Pharmacol. 112:1994;. 489 pp.
84. 1B/1D receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig. Eur. J. Pharmacol. 326:1997;23-30.
85. 1B/D receptor antagonists in dorsal and median raphe innervated brain regions. Eur. J. Pharmacol. 346:1998;175-180.
86. Rodgers R.J., Cole J.C., Cobain M.R., Daly P., Doran P.J., Eells J.R., Wallis P. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav. Pharmacol. 3:1992;621-634.
87. 1B autoreceptors and heteroreceptors and 5-HT-moduline in CNS disorders. CNS Spectrums. 3:1998;50-58.
88. 3H]dopamine from rat striatal synaptosomes. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;40-47.
89. Scearce-Levie K., Chen J.P., Gardner E., Hen R. 5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders. Ann. N. Y. Acad. Sci. 868:1999;701-715.
90. 1B receptors in the rat. Neurosci. Res. 27:1997;277-280.
91. Sheard M.H. The effect of pCPA on behavior in rats: relation to brain serotonin and 5-HIAA. Brain Res. 15:1969;524-528.
92. Sherman A.D., Allers G.L., Petty F., Henn F.A. A neuropharmacologically relevant animal model of depression. Neuropharmacology. 18:1979;891-894.
93. 3H]-imipramine binding in rat cortex. J. Affective Disord. 6:1984;25-32.
94. Sleight A.J., Smith R.J., Marsden C.A., Palfreyman M.G. The effects of chronic treatment with amitriptyline and MDL 72394 on the control of 5-HT release in vivo. Neuropharmacology. 28:1989;477-480.
95. Sleight A.J., Cervenka A., Peroutka S.J. In vivo effects of sumatriptan (GR-43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology. 29:1990;511-513.
96. Soubrié P. Reconciling the role of central serotonin neurons in human and animal behaviour. Behav. Brain. Res. 9:1986;319-364.
97. 1B receptor knockout mice: a review. Int. J. Neuropsychopharmacol. 2:1999;145-150.
98. Stein D.J., Van Heerden B., Wessels C.J., Van Kradenburg J., Warwick J., Wasserman H.J. Single photon emission computed tomography of the brain with Tc-99 m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 23:1999;1079-1099.
99. 1D agonist sumatriptan. Eur. Neuropsychopharmacol. 8:1998;325-328.
100. Tenen S.S. The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behaviour in the rat. Psychopharmacology. 10:1967;204-219.
101. 1D antagonist, enhances 5-HT neurotransmission in guinea pig brain. Soc. Neurosci. 24:1998;1109.
102. Twarog B.M., Page I.H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol. 175:1953;157-161.
103. Vahabzadeh A., Fillenz M. Comparison of stress-induced changes in noradrenergic and serotonergic neurons in the rat hippocampus using microdialysis. Eur. J. Neurosci. 6:1994;1205-1212.
104. Vandijken H.H., Mos J., van der Heyden J.A.M., Tilders F.J.H. Characterization of stress-induced long-term behavioural changes in rats - Evidence in favor of anxiety. Physiol. Behav. 52:1992;945-951.
105. Vandijken H.H., van der Heyden J.A.M., Mos J., Tilders F.J.H. Inescapable footshocks induce progressive and long-lasting behavioural changes in male rats. Physiol. Behav. 51:1992;787-794.
106. Van Riezen H., Leonard B.E. File S.E. Psychopharmacology of Anxiolytics and Antidepressants. 1991;231-250 Pergamon, New York.
107. 1D receptor: a progress review. Neurochem. Res. 15:1990;567-582.
108. 1D receptors in the guinea pig brain: pre- and postsynaptic localizations in the striatonigral pathway. Brain Res. 528:1990;197-206.
109. 1B/1D receptors in psychiatric patients. CNS Spectrums. 3:1998;40-45.
110. Willner P. Behavioural Models in Psychopharmacology. 1991;Cambridge Univ. Press, Cambridge.
111. Wooley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U. S. A. 40:1954;228-231.
112. Yatham L.N., Zis A.P., Lam R.W., Tam E., Shiah I-S. Sumatriptan-induced growth hormone release in patients with major depression, mania and normal controls. Neuropsychopharmacology. 17:1997;258-263.
113. 1D agonist) challenge in seasonal affective disorder: effect of light therapy. Biol. Psychiatry. 42:1997;24-29.
114. Zhuang X., Gross C., Santarelli L., Compan V., Hen R. Altered emotional states in knockout mice lacking the 5-HT-1A or 5-HT-1B receptors. Neuropsychopharmacology. 21(Supplement 2):1999;52S-60S.
115. 1D involved in obsessive-compulsive disorder? Eur. Neuropsychol. 6:1996;54-55.
116. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill J.L., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder: effects of clomipramine treatment. Arch. Gen. Psychiatry. 45:1988;167-172.
117. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., Murphy D.L. Serotonin responsivity in obsessive-compulsive disorder. Arch. Gen. Psychiatry. 44:1987;946-951.
118. Zohar J., Zohar-Kadouch R.C., Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs. 43:1992;210-218.